Agent Capital

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Foresight Diagnostics is a biotechnology company that specializes in developing a novel liquid biopsy test aimed at measuring minimal residual disease to enhance patient management in oncology. The company focuses on early cancer detection through a simple blood sample, leveraging the unique biological features that distinguish cancer cells from healthy cells. This innovative approach enables healthcare professionals to diagnose smaller tumors at an earlier stage, facilitating personalized and effective treatment strategies for patients. Foresight Diagnostics has attracted significant interest from multiple pharmaceutical companies, underscoring its potential impact in the field of cancer diagnostics and treatment.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Founded in 2016 and headquartered in Boston, Massachusetts, with a branch in Cambridge, United Kingdom, Cerevance utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, within mature human brain tissue. By leveraging a substantial repository of over 15,000 human brain samples, the company generates extensive expression and epigenetic data, guiding the identification of promising therapeutic targets. This approach aims to address the early onset of central nervous system diseases by revealing critical transcriptional and epigenetic differences within affected brain regions.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

Cantai Therapeutics operates as a developer of drug candidates.

ViTToria Biotherapeutics is a company focused on developing gene-edited cell therapies, specifically next-generation T-cell therapeutics that aim to address significant unmet medical needs. Utilizing its proprietary Senza5 Technology, ViTToria enhances the efficacy, safety, and overall utility of cell-based treatments in preclinical settings. The company's innovative approach seeks to lower dosing requirements, simplify preconditioning regimens, reduce manufacturing failures, and shorten vein-to-vein times. This technology enables medical practitioners to improve patient outcomes, positioning ViTToria Biotherapeutics as a pioneer in the advancement of cell therapy solutions.

Jana Care, Inc. is a company focused on developing mobile diagnostic solutions for the screening, management, and monitoring of chronic diseases. Its flagship products include The Aina Device, a self-monitoring tool for patients, and The Aina Station, a diagnostic solution for clinics and hospitals. These devices facilitate a range of tests, such as blood glucose, HbA1c, lipid profiles, creatinine, and hemoglobin. Additionally, Jana Care offers The Habits Program, a twelve-week digital coaching initiative aimed at managing diabetes and pre-diabetes. Founded in 2011 and headquartered in Boston, Massachusetts, with an additional office in Bengaluru, India, Jana Care was inspired by a challenge from a physician-entrepreneur to create innovative health solutions for remote communities in India, ultimately evolving into one of the largest chronic disease screening programs globally.

Foresight Diagnostics is a biotechnology company that specializes in developing a novel liquid biopsy test aimed at measuring minimal residual disease to enhance patient management in oncology. The company focuses on early cancer detection through a simple blood sample, leveraging the unique biological features that distinguish cancer cells from healthy cells. This innovative approach enables healthcare professionals to diagnose smaller tumors at an earlier stage, facilitating personalized and effective treatment strategies for patients. Foresight Diagnostics has attracted significant interest from multiple pharmaceutical companies, underscoring its potential impact in the field of cancer diagnostics and treatment.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania, established in 2015. The company specializes in developing and commercializing targeted therapies for serious and rare genetic skin diseases, focusing on addressing the root causes of these conditions. Its lead product candidate, QTORIN, is an anhydrous gel formulated to ensure drug stability at room temperature while enabling effective distribution into skin layers where various dermatologic pathologies occur. Palvella Therapeutics is committed to serving patient populations that have been overlooked, with an initial emphasis on conditions such as microcystic lymphatic malformations and cutaneous venous malformations, leveraging its patented QTORIN platform to advance its therapeutic pipeline.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Carbon Biosciences is a biotechnology company focused on developing genetic medicines aimed at treating serious diseases. The company utilizes a proprietary platform based on novel parvoviruses, which have been optimized through natural selection to effectively target specific tissues and deliver larger therapeutic cargoes. This technology is designed to minimize neutralizing immunity, allowing for potential re-dosing. Carbon Biosciences specifically targets lung tissues and has demonstrated success in preclinical models, including those for cystic fibrosis. Through its industrial-scale viral production platforms, the company aims to extend the reach of gene therapies, providing innovative solutions for previously challenging medical conditions.

ViTToria Biotherapeutics is a company focused on developing gene-edited cell therapies, specifically next-generation T-cell therapeutics that aim to address significant unmet medical needs. Utilizing its proprietary Senza5 Technology, ViTToria enhances the efficacy, safety, and overall utility of cell-based treatments in preclinical settings. The company's innovative approach seeks to lower dosing requirements, simplify preconditioning regimens, reduce manufacturing failures, and shorten vein-to-vein times. This technology enables medical practitioners to improve patient outcomes, positioning ViTToria Biotherapeutics as a pioneer in the advancement of cell therapy solutions.

Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies. Affini-T leverages gene editing and synthetic biology to engineer novel T-cell therapies designed to eradicate tumors.

Cyrus Biotechnology, Inc. is a Seattle-based company that specializes in developing advanced software for protein structure prediction and design. Founded in 2014, it offers several key products, including Rosetta, a tool designed to create biologically active proteins for various medical applications such as treating brain cancer and addressing Celiac Disease. The company also provides Cyrus Bench, an enterprise version of Rosetta that includes a comprehensive suite of bio-molecular computation tools. Additionally, Cyrus Biotechnology offers specialized services like Cyrus CryoEM, which focuses on structure refinement and model building for complex biomolecular structures. Its innovative software solutions cater to pharmaceutical companies, biotech firms, and startups engaged in discovering therapeutics and developing novel consumer products.

Mediar Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2019. It specializes in developing antibody-based therapeutics targeting key fibrotic mediator proteins involved in fibrosis, aiming to halt and potentially reverse this condition in chronically damaged organs. The company operates at the pre-clinical stage.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania, established in 2015. The company specializes in developing and commercializing targeted therapies for serious and rare genetic skin diseases, focusing on addressing the root causes of these conditions. Its lead product candidate, QTORIN, is an anhydrous gel formulated to ensure drug stability at room temperature while enabling effective distribution into skin layers where various dermatologic pathologies occur. Palvella Therapeutics is committed to serving patient populations that have been overlooked, with an initial emphasis on conditions such as microcystic lymphatic malformations and cutaneous venous malformations, leveraging its patented QTORIN platform to advance its therapeutic pipeline.

Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo CAR treatment, which treats B cell lymphomas, is the company's flagship program. Its unique engineering provides exceptional target tissue specificity. The business is working on a second initiative to address autoimmune conditions. With the help of Interius, a novel and distinct therapeutic modality for the precise administration of gene therapies may soon be made available to patients in expanded care settings, without the need for preconditioning chemotherapy.

ImCheck Therapeutics is a biopharmaceutical company based in Marseille, France, that specializes in developing immunotherapeutics aimed at addressing severe unmet medical needs, particularly in the field of immuno-oncology. Founded in 2015, the company focuses on designing and developing immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules. These innovative therapies engage γ9δ2 T cells, a specific type of immune cell, to effectively treat various cancers, including breast, gastric, and ovarian cancers, as well as other solid tumors. Through its advanced research and development efforts, ImCheck Therapeutics seeks to provide next-generation immunotherapeutics for patients suffering from immune-related diseases.

Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.

Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.

Entrada Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on treating diseases through the intracellular delivery of biologics. Founded in 2016, the company has developed innovative technologies that facilitate the efficient delivery of proteins, peptides, and nucleic acids, targeting intracellular sites that have traditionally been difficult to access. Entrada's approach includes Intracellular Enzyme Replacement Therapy (IC-ERT) and Endosomal Escape Vehicle (EEV) therapeutics, which aim to improve the therapeutic index by enabling the delivery of a wide range of therapeutics across various organs and tissues. The company's pipeline addresses conditions related to neuromuscular diseases and expands into additional therapeutic areas, positioning Entrada at the forefront of advancing treatment options for patients with devastating illnesses.

Verge Genomics is a biotechnology company focused on transforming drug discovery through the application of artificial intelligence. Founded by experts in machine learning and seasoned neuroscience drug developers, the company aims to leverage advancements in computational genomics and insights into neuroscience to discover innovative therapeutics for neurodegenerative diseases. Its drug discovery platform employs machine learning algorithms to analyze large datasets, identifying potential drug targets and predicting effective treatments. By accelerating the development of life-saving therapies, Verge Genomics seeks to enhance patient outcomes and reduce the costs associated with pharmaceutical development, thereby addressing critical challenges in the healthcare sector.

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing innovative therapies for fibrotic diseases. Its lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both indications and is currently undergoing Phase 2a clinical trials. The company is also developing PLN-1474, a small-molecule selective inhibitor of avß1, for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, which is in Phase 1 trials. Founded in 2015, Pliant Therapeutics is also advancing preclinical programs aimed at addressing oncology and muscular dystrophies.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Skyhawk Therapeutics, Inc. is a biotechnology company focused on the discovery and development of small molecule therapeutics that aim to correct RNA expression. The company's proprietary technology facilitates the rational design of these small molecules to target specific binding pocket regions on RNA, employing both sequence and structural specificity at critical moments during the RNA splicing process. This innovative approach allows for the targeting of diseases associated with RNA mis-splicing, particularly those characterized by exon skipping. Skyhawk Therapeutics is committed to developing treatments for various conditions, including cancer, neurological diseases, and rare disorders. Founded in 2015 and headquartered in Waltham, Massachusetts, the company has evolved from its initial identity as Rare Genetix, Inc., adopting its current name in May 2018.

Hinge Bio is a biotechnology company based in Burlingame, California, founded in 2015. The company specializes in developing bispecific and multispecific antibodies using its proprietary Flex-Hinge antibody platform. This platform enables the creation of therapeutic candidates with enhanced affinity and specificity through a chemical ligation process technology. Hinge Bio's approach allows for the production of therapeutics that can simultaneously bind to multiple disease targets, making it applicable to various conditions including oncology, metabolic diseases, and neurodegenerative disorders.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

Orbus Therapeutics, Inc., established in 2012 and based in Palo Alto, California, is a biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases, with a focus on brain cancers. Its lead product, Eflornithine, is an orally bioavailable small molecule that acts as a cytostatic agent, inhibiting tumor growth by targeting ornithine decarboxylase (ODC). Currently, Orbus Therapeutics is working to bring Eflornithine to patients in North America affected by recurrent anaplastic astrocytoma, a rare and life-threatening form of central nervous system cancer. The company's mission is to improve the health and quality of life for these underserved patients by delivering innovative products that offer more positive outcomes.

Dragonfly Therapeutics, Inc. is a clinical-stage biotechnology company based in Waltham, Massachusetts, founded in 2015. The company specializes in developing innovative therapeutics that stimulate immune responses against cancer, utilizing its proprietary TriNKET platform. Dragonfly's approach focuses on harnessing the power of natural killer cells and other components of the innate immune system to counteract the immune suppressive factors found in the tumor microenvironment. Its drug candidates are designed to be effective both as standalone treatments and in combination with existing cancer immunotherapies. The company has established strategic collaborations with major pharmaceutical firms, including Celgene Corporation and Merck, to further advance its therapeutic offerings. Dragonfly Therapeutics aims to provide breakthrough cancer treatments, informed by the expertise of its scientific founders, who are recognized leaders in cancer biology and immunology.

GlycoEra is a biotechnology research company focused on developing innovative therapeutics that target significant unmet medical needs in inflammatory and autoimmune diseases, as well as in immune-oncology. The company has established a proprietary platform that enables the creation of first-in-class biologics by assembling customized and highly homogeneous human glycans onto glycoproteins in a site-specific manner. This approach facilitates a deeper understanding of the role of glycans in human health and disease, positioning GlycoEra to contribute meaningfully to the advancement of novel treatment options in the healthcare sector.